HomeLatest NewsCovid-19FDA authorizes Remdesivir for Certain Non-Hospitalized Patients, New At-Home Test for COVID-19

FDA authorizes Remdesivir for Certain Non-Hospitalized Patients, New At-Home Test for COVID-19

The Food and Drug Administration Friday expanded the approved uses for Vekury (remdesivir) to include non-hospitalized patients aged 12 and older who test positive for SARS-CoV-2, weigh at least 88 pounds and are at high risk of progressing to severe COVID-19. The agency also authorized emergency use of the drug for high-risk, non-hospitalized pediatric patients who weigh less than 88 but more than 8 pounds, including patients under age 12. The drug previously was limited to hospitalized patients. The expanded uses are based on results from a clinical trial that showed the drug reduced hospitalizations in high-risk, non-hospitalized patients. For more information, see the updated provider and patient fact sheets.

Last week the FDA issued an emergency use authorization for another over-the-counter COVID-19 test, MaximBio ClearDetect COVID-19 Antigen Home Test, that delivers results in 15 minutes.

Stay Connected

Unified Voice Newsletter

Events This Month

Current Month

November

13nov12:00 pm1:30 pmPolicy SimplificationSDAHO Webinar

14nov12:00 pm1:30 pmEHR Simplification and DocumentationSDAHO Webinar

14nov1:30 pm2:30 pmUse of Artificial Intelligence (AI) in Serious Illness CommunicationMJHS Palliative Care Webinar

14nov3:00 pm4:00 pmHow to Support and Empower Caregivers of People Living with DementiaCAPC Webinar

18nov2:00 pm3:00 pmMeeting the CMS Age-Friendly Hospital Measure in the Geriatric Emergency DepartmentWebinar